Health Care

Gilead's twice-yearly shot cut HIV infections by 96% in trial

The data sets the stage for likely approval of Gilead's Lenacapavir for HIV prevention.

adminadmin
Sep 12, 2024 - 22:00
 0  11
Gilead's twice-yearly shot cut HIV infections by 96% in trial
The data sets the stage for likely approval of Gilead's Lenacapavir for HIV prevention.
Read More

Tags:

Previous Article

Moderna shares plunge on plans to cut $1.1 billion in costs, launch 10 new produ...

Next Article

Apple turning AirPods into hearing aids underscores effort to crack massive heal...

admin
admin

Related Posts

Amazon launches fixed pricing for treatment of conditions such as hair loss. Hims & Hers stock drops 24%

Amazon launches fixed pricing for treatment of conditio...

admin Nov 15, 2024  0  3

CVS is working with advisors on strategic review, sources say

CVS is working with advisors on strategic review, sourc...

admin Oct 1, 2024  0  10

CDC issues dengue fever alert in the U.S.

CDC issues dengue fever alert in the U.S.

admin Jun 26, 2024  0  17